Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14501426 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL3460266 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL1031685 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL15603335 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL15603406 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL13697136 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL15603391 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL14416499 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL1031687 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL1828824 | 1.00 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160397-B1 | A NOVEL AND HIGHLY STEREOSELECTIVE PROCESS FOR PREPARING GEMCITABINE AND INTERMEDIATES THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2014-03-26 | — | — | EP | claimed |
| US-8212021-B2 | Process for making 5-azacytosine nucleosides and their derivatives | SCINOPHARM TAIWAN, LTD. (TW) | 2012-07-03 | — | — | US | disclosed |
| US-20100036112-A1 | Process for Making 5-Azacytosine Nucleosides and Their Derivatives | SCINOPHARM TAIWAN LTD. | 2010-02-11 | — | — | US | disclosed |
| US-4681873-A | 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds | WARNER-LAMBERT COMPANY (US) | 1987-07-21 | — | — | US | disclosed |
| EP-0210639-A2 | 4-Amino-3-halo-2-pyridinone nucleoside and nucleotide compounds | WARNER-LAMBERT COMPANY (US) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036112-A1 | Process for Making 5-Azacytosine Nucleosides and Their Derivatives | DCTD, DUT, DPYD | CDA 7/4885PDE4D 1182/4885PDE3A 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.